Biomarker and Alzheimer disease: role of high sensitivity assays and the applications

Alzheimer disease is a devastating neurodegenerative disease, which is the only one amongst the top 10 deadly diseases that has almost no treatment. FDA approved ADUHELM® from Biogen in 2021 was the first approved Alzheimer treatment in the past 2 decades.

Current treatment plans focus on two strategies, preventing the formation and aggregation of plague proteins called amyloids and taus, or removing such proteins. ADUHELM® adopted the later pathway. Meanwhile, from the diagnostic point-of-view, we are slightly ahead of time compared with the treatment, thanks to various new technologies. In particular, highly sensitive technology and platforms enable early diagnostics.

It has been said that the diagnosis of Alzheimer disease enters the era of biomarkers. These two biomarkers, amyloids and taus, defines Alzheimer disease. This presentation will focus on highly sensitive protein biomarker assays developed and validated at a testing laboratory and its application for the diagnosis of Alzheimer disease